Prahalathan Pichavaram

Prahalathan Pichavaram

Auto-generated profile, based on publicly available information

Prahalathan Pichavaram

Department of Surgery, St. Jude Children's Research Hospital, Memphis, Tennessee

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2023 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
PPPrahalathan Pichavaram
Prahalathan Pichavaram
CJCarolyn M. Jablonowski
Carolyn M. Jablonowski
JFJie Fang
Jie Fang
AFAndrew M Fleming
Andrew M Fleming
HGHyea Jin Gil
Hyea Jin Gil
AMAndrew Murphy
Andrew Murphy
The histone lysine demethylases KDM4A-C are involved in physiologic processes including stem cell identity and self-renewal during development, DNA damage repair, and cell-cycle progression. KDM4A-C are overexpressed and associated with malignant cell behavior in multiple human cancers and are therefore potential therapeutic targets. Given the role of KDM4A-C in development and cancer, we aimed to test the potent, selective KDM4A-C inhibitor QC6352 on oncogenic cells of renal embryonic lineage. The anaplastic Wilms tumor cell line WiT49 and the tumor-forming human embryonic kidney cell line HEK293 demonstrated low nanomolar QC6352 sensitivity. The cytostatic response to QC6352 in WiT49 and HEK293 cells was marked by induction of DNA damage, a DNA repair–associated protein checkpoint response, S-phase cell-cycle arrest, profound reduction of ribosomal protein gene and rRNA transcription, and blockade of newly synthesized proteins. QC6352 caused reduction of KDM4A-C levels by a proteasome-associated mechanism. The cellular phenotype caused by QC6352 treatment of reduced migration, proliferation, tumor spheroid growth, DNA damage, and S-phase cell-cycle arrest was most closely mirrored by knockdown of KDM4A as determined by siRNA knockdown of KDM4A-C. QC6352 sensitivity correlated with high basal levels of ribosomal gene transcription in more than 900 human cancer cell lines. Targeting KDM4A may be of future therapeutic interest in oncogenic cells of embryonic renal lineage or cells with high basal expression of ribosomal protein genes.

17 June 2026
Verified
Other
Open access
PPPrahalathan Pichavaram
Prahalathan Pichavaram
CJCarolyn M. Jablonowski
Carolyn M. Jablonowski
JFJie Fang
Jie Fang
AFAndrew M Fleming
Andrew M Fleming
HGHyea Jin Gil
Hyea Jin Gil
AMAndrew Murphy
Andrew Murphy
Gene set enrichment analysis demonstrated significant downregulation of the REACTOME_EUKARYOTIC_TRANSLATION_INITIATION and REACTOME_PRC2_METHYLATES_HISTONES_AND_DNA pathways in QC6352-treated WiT49 cells and the REACTOME_EUKARYOTIC_TRANSLATION_INITIATION pathway in HEK293 cells.


17 June 2026
Verified
Other
Open access
PPPrahalathan Pichavaram
Prahalathan Pichavaram
CJCarolyn M. Jablonowski
Carolyn M. Jablonowski
JFJie Fang
Jie Fang
AFAndrew M Fleming
Andrew M Fleming
HGHyea Jin Gil
Hyea Jin Gil
AMAndrew Murphy
Andrew Murphy
Transmission electron microscopy demonstrates that 25 nM QC6352 treatment for 72 hours caused a structural change resulting in less compact nucleoli WiT49 and HEK293 cells. More compact nucleoli with dense/compact fibrillar centers are known to be more active. Nuclear membranes indicated with black arrows and nucleoli are labeled.

17 June 2026
Verified
Other
Open access
PPPrahalathan Pichavaram
Prahalathan Pichavaram
CJCarolyn M. Jablonowski
Carolyn M. Jablonowski
JFJie Fang
Jie Fang
AFAndrew M Fleming
Andrew M Fleming
HGHyea Jin Gil
Hyea Jin Gil
AMAndrew Murphy
Andrew Murphy
QC6352 treatment (25nM x 72 hours) reduces nucleoli in WiT49 and HEK293. (A) KDM4A (red) and the nucleolar marker fibrillarin (green) co-localize in the nucleoli [also represented by areas of reduced DAPI staining (blue) in the nucleus due to incompact chromatin in nucleoli] in WiT49 cells. (B) QC6352 treatment caused a reduction in the fibrillarin/nuclear area (determined by the area of fibrillarin/area DAPI) in WiT49 cells (p<0.0001), representing a reduction of nucleoli. (C) Similar findings were found in QC6352-treated HEK293 cells, which also exhibited a (D) reduction of the fibrillarin/nuclear area (p<0.0001).

17 June 2026
Verified
Other
Open access
PPPrahalathan Pichavaram
Prahalathan Pichavaram
CJCarolyn M. Jablonowski
Carolyn M. Jablonowski
JFJie Fang
Jie Fang
AFAndrew M Fleming
Andrew M Fleming
HGHyea Jin Gil
Hyea Jin Gil
AMAndrew Murphy
Andrew Murphy
Gene set enrichment analysis demonstrated significant alteration of the GO_CHROMATIN_SILENCING_AT_RDNA pathways in WiT49 and HEK293 cells treated with QC6352.